Visterra, Inc. Appoints Two Industry Leaders To Its Board Of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Visterra, Inc., a clinical-stage biotechnology company, today announced the appointment of Bernadette Connaughton, Head, European Markets, Canada and Australia of Bristol-Myers Squibb, and Steven Holtzman, former Executive Vice President, Corporate Development of Biogen, to the company’s board of directors. Ms. Connaughton and Mr. Holtzman each bring more than 30 years of strategic, operational and management experience in the biopharmaceutical industry to Visterra’s board and, in particular, experience in growing and leading companies and business units to generate significant value, as well as deep understanding of global pharmaceutical markets.

Back to news